Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoinflammatory and Inflammasome-Targeted Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MEFV drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MEFV Recombinant Protein (WT & Clinical Mutants like M694V, V726A) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Domain-specific constructs (PYD, B30.2/SPRY). |
View MEFV Products |
| Gene Delivery | MEFV Promise-ORF / Lentivirus Full-length ORF (WT and mutant variants) for stable cell line generation. |
View MEFV Products |
| Benchmark Ab | Anti-MEFV Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP. |
View MEFV Products |
| Validator | MEFV siRNA Set For knockdown verification in functional inflammasome assays. |
View MEFV Products |
| Related Target A | NLRP3 Key parallel inflammasome pathway; crucial for selectivity and cross-talk screening. |
View NLRP3 Products |
| Related Target B | IL1B (IL-1 beta) Primary downstream effector cytokine cleaved and released upon Pyrin inflammasome activation. |
View IL1B Products |
| Related Target C | Caspase-1 The protease activated by the Pyrin/ASC complex, responsible for processing IL-1 beta and Gasdermin D. |
View Caspase-1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational stability of intracellular Pyrin domains | Domain-specific recombinant proteins (PYD, SPRY) strictly verified by SDS-PAGE and Mass Spectrometry for structural integrity. |
| Screening for mutation-specific drug resistance/sensitivity | Point-mutant proteins (M694V, V726A, M680I) engineered and sequence-verified to match clinical autoinflammatory profiles. |
| Lack of reliable positive controls | High-affinity recombinant benchmark antibodies available for robust target validation. |
| Off-target inflammasome activation/inhibition | A comprehensive counter-screening panel including NLRP3, NLRC4, and AIM2 reagents. |
Live MEFV R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MEFV (Pyrin) therapeutics is intensifying, with major players shifting focus from traditional downstream cytokine blockade (such as anti-IL-1 therapies) to direct small-molecule modulation of the Pyrin inflammasome. As first-generation systemic anti-inflammatory therapies reach clinical maturity, the next wave of R&D is targeting direct Pyrin regulators to treat Familial Mediterranean Fever (FMF) and broader autoinflammatory conditions without inducing systemic immunosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Novartis, Inflazome (Roche) | FMF, Gout, Cardiovascular Inflammation | Selectivity assays (Need mutant vs WT proteins to evaluate allele-specific binding) |
| Gene Therapy / Editing | Academic Institutes, Biotech Startups | Severe refractory FMF | Lentiviral-mediated expression validation (Need sequence-verified MEFV lentivirus) |
| Biologics (Downstream) | Sobi, Regeneron | Systemic Autoinflammatory Diseases | Functional validation in reporter cells (Need IL1B and Caspase-1 detection reagents) |